Biocon Ltd. stock analysis & expert insights in detailCan Biocon Ltd’s transition toward complex generics and biosimilars, improving product mix, disciplined cost and balance-sheet management, and sharper focus on regulated and high-value global markets drive a sustained earnings recovery and long-term value creation? Let’s explore.
India’s pharmaceutical landscape is steadily moving up the value chain, from generics to complex biologics and specialty therapies. At the center of this transition...